James A Dykens

Summary

Publications

  1. ncbi request reprint Development of 17alpha-estradiol as a neuroprotective therapeutic agent: rationale and results from a phase I clinical study
    James A Dykens
    MIGENIX Corporation, 12780 High Bluff Dr, San Diego, CA 92130, USA
    Ann N Y Acad Sci 1052:116-35. 2005
  2. ncbi request reprint Photoreceptor preservation in the S334ter model of retinitis pigmentosa by a novel estradiol analog
    James A Dykens
    MitoKor Inc, 11494 Sorrento Valley Road, San Diego, CA 92121, USA
    Biochem Pharmacol 68:1971-84. 2004
  3. ncbi request reprint Strategies to reduce late-stage drug attrition due to mitochondrial toxicity
    James A Dykens
    Pfizer DSRD, 10646 Science Center Drive, San Diego, CA 92121, USA
    Expert Rev Mol Diagn 7:161-75. 2007
  4. ncbi request reprint Oxidative damage to human lens epithelial cells in culture: estrogen protection of mitochondrial potential, ATP, and cell viability
    Xiaofei Wang
    Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, Texas 76107, USA
    Invest Ophthalmol Vis Sci 44:2067-75. 2003
  5. ncbi request reprint Mitochondria play a central role in estrogen-induced neuroprotection
    James W Simpkins
    Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX 76102, USA
    Curr Drug Targets CNS Neurol Disord 4:69-83. 2005
  6. ncbi request reprint Neuroprotective effects of 17beta-estradiol and nonfeminizing estrogens against H2O2 toxicity in human neuroblastoma SK-N-SH cells
    Xiaofei Wang
    Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, 3500 Camp Bowie Blvd, Fort Worth, TX 76107, USA
    Mol Pharmacol 70:395-404. 2006
  7. ncbi request reprint Novel mechanisms for estrogen-induced neuroprotection
    Meharvan Singh
    Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX 76107, USA
    Exp Biol Med (Maywood) 231:514-21. 2006
  8. ncbi request reprint Mitochondrial mechanisms of estrogen neuroprotection
    James W Simpkins
    Department of Pharmacology and Neuroscience, Institute for Aging and Alzheimer s Disease Research, University of North Texas Health Science Center, 3500 Camp Bowie Boul, Fort Worth, TX 76102, USA
    Brain Res Rev 57:421-30. 2008
  9. ncbi request reprint The significance of mitochondrial toxicity testing in drug development
    James A Dykens
    Drug Safety Research and Development, Pfizer Inc, 10646 Science Center Drive, San Diego, CA 92121, United States
    Drug Discov Today 12:777-85. 2007

Collaborators

Detail Information

Publications9

  1. ncbi request reprint Development of 17alpha-estradiol as a neuroprotective therapeutic agent: rationale and results from a phase I clinical study
    James A Dykens
    MIGENIX Corporation, 12780 High Bluff Dr, San Diego, CA 92130, USA
    Ann N Y Acad Sci 1052:116-35. 2005
    ..Positive safety and pharmacokinetic data from a successful phase I clinical study with oral 17alpha-E2 (sodium sulfate conjugate) are presented here, and several options for its future clinical assessment are discussed...
  2. ncbi request reprint Photoreceptor preservation in the S334ter model of retinitis pigmentosa by a novel estradiol analog
    James A Dykens
    MitoKor Inc, 11494 Sorrento Valley Road, San Diego, CA 92121, USA
    Biochem Pharmacol 68:1971-84. 2004
    ..Mitochondrial interventions offer a novel therapeutic approach for RP, and other degenerative diseases of the retina...
  3. ncbi request reprint Strategies to reduce late-stage drug attrition due to mitochondrial toxicity
    James A Dykens
    Pfizer DSRD, 10646 Science Center Drive, San Diego, CA 92121, USA
    Expert Rev Mol Diagn 7:161-75. 2007
    ..This dichotomy encourages optimism that efficacy can be disassociated from mitochondrial toxicity, resulting in safer drugs in the future...
  4. ncbi request reprint Oxidative damage to human lens epithelial cells in culture: estrogen protection of mitochondrial potential, ATP, and cell viability
    Xiaofei Wang
    Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, Texas 76107, USA
    Invest Ophthalmol Vis Sci 44:2067-75. 2003
    ..In the present study, for the first time, the protective effect of estrogens against oxidative stress were tested in cultured human lens epithelial cells (HLECs)...
  5. ncbi request reprint Mitochondria play a central role in estrogen-induced neuroprotection
    James W Simpkins
    Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX 76102, USA
    Curr Drug Targets CNS Neurol Disord 4:69-83. 2005
    ....
  6. ncbi request reprint Neuroprotective effects of 17beta-estradiol and nonfeminizing estrogens against H2O2 toxicity in human neuroblastoma SK-N-SH cells
    Xiaofei Wang
    Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, 3500 Camp Bowie Blvd, Fort Worth, TX 76107, USA
    Mol Pharmacol 70:395-404. 2006
    ..In conclusion, estrogens exert protective effects against oxidative stress by inhibiting lipid peroxidation and subsequently preserving Ca2+ homeostasis, mitochondrial membrane potential, and ATP levels...
  7. ncbi request reprint Novel mechanisms for estrogen-induced neuroprotection
    Meharvan Singh
    Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX 76107, USA
    Exp Biol Med (Maywood) 231:514-21. 2006
    ..On the basis of this evidence, we discuss the clinical applicability of estrogens in treating various age-related disorders, including Alzheimer disease and stroke, and identify the caveats that must be considered...
  8. ncbi request reprint Mitochondrial mechanisms of estrogen neuroprotection
    James W Simpkins
    Department of Pharmacology and Neuroscience, Institute for Aging and Alzheimer s Disease Research, University of North Texas Health Science Center, 3500 Camp Bowie Boul, Fort Worth, TX 76102, USA
    Brain Res Rev 57:421-30. 2008
    ....
  9. ncbi request reprint The significance of mitochondrial toxicity testing in drug development
    James A Dykens
    Drug Safety Research and Development, Pfizer Inc, 10646 Science Center Drive, San Diego, CA 92121, United States
    Drug Discov Today 12:777-85. 2007
    ....